



# ANCA Glomerulonephritis after COVID-19 and post-COVID-19 vaccination – current state of knowledge

Justyna Małgorzata Tomasik<sup>1,A-D,F</sup>✉, Piotr Sajdak<sup>2,3,B,D-E</sup>, Seweryn Ziajor<sup>3,C-D</sup>,  
Mikołaj Turski<sup>4,D,F</sup>, Artur Bednarski<sup>5,B-C</sup>, Marika Dębik<sup>6,B,E</sup>, Marcel Stodolak<sup>4,D-E</sup>,  
Łukasz Szydłowski<sup>7,D</sup>, Aleksandra Krużel<sup>8,D</sup>, Klaudia Żurowska<sup>9,C</sup>, Kamil Kłós<sup>8,D</sup>

<sup>1</sup> Medical University, Lublin, Poland

<sup>2</sup> Morphological Sciences Department, Institute of Medical Sciences, Medical College of the University, Rzeszów, Poland

<sup>3</sup> Medical Centre, Łańcut, Poland

<sup>4</sup> E. Szczeklik Specialist Hospital, Tarnów, Poland

<sup>5</sup> F. Chopin University Clinical Hospital, Rzeszów, Poland

<sup>6</sup> Provincial Specialist Hospital, Research and Development Centre, Wrocław, Poland

<sup>7</sup> Polish Red Cross Maritime Hospital, Gdynia, Poland

<sup>8</sup> Medical University of Silesia, Katowice, Poland

<sup>9</sup> T. Marciniak Lower Silesian Specialist Hospital – Emergency Medicine Centre, Wrocław, Poland

A – Research concept and design, B – Collection and/or assembly of data, C – Data analysis and interpretation, D – Writing the article, E – Critical revision of the article, F – Final approval of the article

Tomasik JM, Sajdak P, Ziajor S, Turski M, Bednarski A, Dębik M, Stodolak M, Szydłowski Ł, Krużel A, Żurowska K, Kłós K. ANCA Glomerulonephritis after COVID-19 and post-COVID-19 vaccination – current state of knowledge. *J Pre-Clin Clin Res.* 2024; 18(1): 66–72. doi: 10.26444/jpccr/186198

## Abstract

**Introduction and Objective.** In recent years, cases of secondary glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA-GN) have been reported following COVID-19 infection or vaccination against SARS-CoV-2. The aim of the study was to analyze publications related to this issue and to highlight both the benefits of vaccination and the potential for secondary immune responses to both infection and vaccination against COVID-19.

**Review Methods.** A literature review was conducted on sources available up to December 2023, utilizing databases such as PubMed, Cochrane, and Google Scholar. The analysis included cases of ANCA-associated glomerulonephritis (ANCA-GN) following SARS-CoV-2 infection and after COVID-19 vaccination.

**Brief description of the state of knowledge.** ANCA-associated vasculitis (AAV) is an inflammation of small and medium vessels affecting all systems, including the kidneys. Various causes contribute to the development of AAV, including pathogenic microorganisms and individual abnormal reactions to vaccinations, which can lead to autoimmunization. Since the Covid-19 pandemic, cases of ANCA-GN have been observed in patients without prior autoimmune diseases. The rapid progression of the COVID-19 pandemic led to a significant acceleration in the development of dedicated vaccines, thereby preventing a considerable number of deaths caused by the infection.

**Summary.** ANCA-associated glomerulonephritis post COVID-19 can be linked to both infection and vaccination, which may act as triggers for autoimmune responses. These mechanisms require further investigation. Vaccine-induced ANCA-GN following COVID-19 vaccination is rare, and vaccinations represent an appropriate strategy to combat this disease.

## Key words

COVID-19, SARS-CoV-2 vaccination, ANCA-associated autoimmune glomerulonephritis, ANCA-associated vasculitis

## INTRODUCTION

Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated glomerulonephritis is a severe form of glomerulopathy that can occur at any age. It is associated with systemic vasculitis linked to ANCA (AAV), involving renal glomeruli [1]. The disease progresses rapidly, often presenting with asymptomatic haematuria, proteinuria of varying severity, leading to acute renal failure. Renal biopsy typically reveals focal and segmental glomerulonephritis, as well as diffuse necrotizing and crescentic glomerulonephritis. The most crucial approach is rapid diagnosis and initiation of appropriate immunosuppressive treatment [2, 3].

Various factors can trigger autoimmune reactions, including infectious agents and even vaccines, which may contribute to the development of AAV and autoimmunization [4]. Several cases of ANCA-associated vasculitis of the kidneys following COVID-19 illness and induced by the COVID-19 vaccine have been described in the literature [5].

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, began in December 2019 when the first cases of the disease were identified in Wuhan, Hubei province, China. The World Health Organization (WHO) recognized COVID-19 as a global public health threat [6, 7]. As of January 2024, the total confirmed case count is 773 million and continues to rise [8].

SARS-CoV-2 not only targets the respiratory system but can also affect other organs, and may be associated with the *de novo* development of autoimmune diseases [9]. A study by Cheng Y. and colleagues from the Nephrology Department

✉ Address for correspondence: Justyna Małgorzata Tomasik, Medical University, Aleje Raclawickie 1, 20-059 Lublin, Poland  
E-mail: j.tomasik1995@gmail.com

Received: 29.01.2024; accepted: 18.03.2024; online publication: 26.03.2024

in Wuhan, China, determined that 44% of patients with COVID-19 developed proteinuria and haematuria, indicating the development of renal failure [10]. It has been established that SARS-CoV-2 infection is associated with various forms of renal involvement, causing injuries to renal tubules, interstitial nephritis, and glomerular diseases. Moreover, several cases of ANCA-associated glomerulonephritis (ANCA-GN) were observed post-COVID-19 infection, related to anti-neutrophil cytoplasmic antibodies (ANCA) [11 – 13].

The rapid increase in morbidity and mortality due to the SARS-CoV-2 pandemic led to a significant acceleration in vaccine development time from 10 – 15 years to 1 – 2 years, raising concerns among patients about the safety profile of these vaccines [14, 15]. We now know that vaccination, including the mRNA BNT162b2 (Pfizer-BioNTech) vaccine, has shown 95% efficacy against COVID-19 in individuals aged 16 and older. A favourable safety profile was observed during the first phase of the BNT162b2 study, confirmed in the phase 2/3 part of the trial, and was similar to that of other viral vaccines [16].

The aim of this study was to analyze publications related to secondary ANCA-associated glomerulonephritis (ANCA-GN) following COVID-19 illness or vaccination against SARS-Cov-2. Attention was paid to both the benefits of vaccination and the possibilities of secondary immune reactions to infection and vaccination against COVID-19. By highlighting this clinical issue, this study may contribute to faster diagnosis and the implementation of appropriate treatment.

## MATERIALS AND METHOD

A literature review of publications from 2018 – 2023 was conducted using PubMed, Cronarche, and Google Scholar databases, without language restrictions. Articles were selected using the following key words: COVID-19, SARS-CoV-2 vaccination, ANCA-associated autoimmune glomerulonephritis, ANCA-associated vasculitis. The analysis included cases of ANCA-associated glomerulonephritis (ANCA-GN) related to anti-neutrophil cytoplasmic antibodies (ANCA) following SARS-CoV-2 infection and post COVID-19 vaccination, which were confirmed by biopsy.

## DESCRIPTION OF THE STATE OF KNOWLEDGE

**Glomerulonephritis associated with Anti-Neutrophil Cytoplasmic Antibodies (ANCA-GN).** ANCA-associated vasculitis is a group of autoimmune diseases characterized by necrotizing inflammation of small blood vessels, such as arterioles, venules, and capillaries, as well as medium-sized vessels, although the latter are less frequently involved in the disease process. The disease is marked by the development of autoantibodies against neutrophil leukocyte proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA) [17].

ANCA-associated vasculitis (AAV) is a rare disease, occurring at a frequency of about 20 cases per million population per year in Europe and North America, with a slight male predominance. Incidence increases with age, peaking in the 60 – 70 age group [18].

In AAV, involvement of all organ systems can occur. Besides the kidneys, AAV often affects the upper and lower

respiratory tract, skin, and nervous system. Microscopic polyangiitis (MPA) is the most common disease involving the kidneys in AAV. About 90% of patients with MPA have renal involvement. Vasculitis limited only to the kidneys is a rare form of AAV. Renal biopsy typically reveals focal necrotizing glomerulonephritis with crescents, without deposition of immune complexes. Additionally, patients often present with microscopic haematuria with active urinary sediment, usually non-nephrotic range proteinuria, and elevated creatinine levels. Resistant hypertension is also common. There is a reduction in glomerular filtration and a decrease in GFR, even within a few days [3, 17, 19]. Changes progress at a rapid pace, leading to progression to end-stage renal failure if the disease is not recognized and treated early. Untreated patients have a very high mortality rate, reaching up to 90% [20]. The classification of primary vasculitides according to the 2012 Chapel Hill Consensus, is presented in Tab. 1 [21].

**Table 1.** Classification of primary vasculitides according to the 2012 Chapel Hill Consensus [21]

Primary Vasculitis Associated with Anti-Neutrophil Cytoplasmic Antibodies (ANCA) [21].		
Granulomatosis with Polyangiitis (GPA)	Microscopic polyangiitis (MPA)	Eosinophilic granulomatosis with polyangiitis (EGPA)

Based on genetic and immunological studies, a different classification of ANCA-associated vasculitis (AAV) has been established: PR3-positive AAV (PR3-AAV), MPO-positive AAV (MPO-AAV), and in cases with the presence or absence of ANCA – respectively (ANCA+) or (ANCA-) [22]. The type of ANCA antibodies is one of the key factors determining the course of the disease and affects renal function, response to treatment, and the possibility of recurrence. In the case of PR3-ANCA antibody disease, there is often acute renal injury, with greater resistance to treatment and more frequent relapses. Patients with positive MPO-ANCA test results tend to have a milder form of the disease, with a tendency to progress to chronic renal failure [17, 18]. Table 2 presents a comparison of vasculitis depending on the type of antibodies [1].

**Table 2.** Comparison of vasculitis depending on the type of antibodies [1]

Characteristic for Comparison in Vasculitis	Type of ANCA Antibodies in Vasculitis	
	PR3-ANCA	MPO-ANCA
Area of prevalence	Northern Europe, Northern North America, and Australia	Southern Europe, Southern USA and Asia
HLA system	Genetic association with HLA-DP	Genetic association with HLA-DQ
Most commonly affected system	Upper respiratory tract	Kidneys
Type of inflammation	More characteristics of granulomatous inflammation	Fewer characteristics of granulomatous inflammation
Vascular features in biopsy	More characteristics of necrosis	More characteristics of sclerosis

The etiology and pathogenesis of ANCA-associated vasculitis (AAV) are multifactorial and not fully understood. Factors such as infections, drugs, vaccines, exposure to environmental antigens, and genetic predisposition may

contribute to increased immunization [21, 22]. There is insufficient knowledge about the primary cause of the autoimmune response that leads to ANCA production. Genome-wide association studies in patients with ANCA vasculitis have shown specific and different HLA associations with MPO-ANCA and PR3-ANCA vasculitis. It has been confirmed that genetic factors account for 20% of the risk of developing ANCA-associated vasculitis [23]. The human leukocyte antigen (HLA), PTPN22, CTLA-4, IL-10, and TLR9 are thought to be associated with the development of ANCA-positive vasculitis. Genome-wide association studies in eosinophilic granulomatosis and vasculitis reveal genetic subgroups: the MPO-ANCA+ subgroup strongly associated with HLA-DQ and the MPO-ANCA subgroup associated with regions such as GPA33 and IL5/IRF1 [24, 25].

In the genesis of ANCA autoimmunization, epigenetically-controlled increased expression of ANCA autoantigens plays a significant role. As a result of epigenetic dysregulation, MPO and PRTN3 genes in neutrophils and peripheral blood monocytes are over-expressed in patients with active ANCA vasculitis, compared to patients in remission and healthy individuals. Increased expression of MPO and PR3 genes likely influences the pathogenesis of the disease through two mechanisms – enhanced ANCA-induced neutrophil activation or stimulation of a pathogenic autoimmune response. These two processes may also occur simultaneously. However, it is known that both the acquired and innate immune systems are responsible for inducing ANCA vasculitis [1, 18]. Furthermore, in the pathogenesis of AAV, the loss of tolerance to neutrophil proteins has been proven, leading to activation, recruitment, and damage to neutrophils mediated by ANCA antibodies. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) also participates in this process [22]. Single nucleotide polymorphism in protein tyrosine phosphatase (PTPN22), Toll-like receptor 9, Fc gamma receptors, interleukin-10 and 2, are also associated with the occurrence of ANCA-associated vasculitis [3].

Single cases of vaccine-induced ANCA-associated vasculitis (AAV), specifically from influenza vaccination, have been described in the literature which, however, should not question the positive role of vaccinations. A research group led by Lisa S. Jeffs from the Institute of Medical and Veterinary Science in Adelaide, Australia, reported a case where a patient developed an excessive immune response and production of PR3-ANCA following an influenza vaccination with a vaccine containing viral ribonucleic acid. It is possible that the patient already had these antibodies before vaccination, and the procedure only initiated the immunological process and symptom [26]. This hypothesis is supported by a study by Huugen D. et al. on anti-myeloperoxidase IgG-induced glomerulonephritis in a mouse model, where pro-inflammatory stimuli intensified the development of glomerulonephritis [27].

The study by Lee et al. demonstrates the impact of HBV infection on the development of ANCA-associated vasculitis. It was observed that the initial disease was more severe and there was a higher frequency of relapses (RR 16, p 0.016?) compared to patients without prior HBV infection [28]. Iyoda et al. in their study demonstrated a link between severe Chlamydia pneumoniae infection and subsequent development of ANCA-associated glomerulonephritis. Positive Chlamydia pneumoniae IgM antibodies were found in 33% of the patients with MPO-ANCA-associated vasculitis

[29]. Furthermore, numerous studies have been conducted to detect the relationship between chronic Staphylococcus aureus carriage in the pathogenesis of ANCA-associated vasculitis. A study by Stegeman and colleagues showed that chronic Staphylococcus aureus carriage is associated with an increased risk of relapse of this disease [4, 30]. In the study by Scott J. et al., various factors influencing the development of ANCA-associated vasculitis were summarized. It suggests that in addition to viral and bacterial infections, environmental contamination, UV radiation, and harmful working conditions can also contribute to the development of autoimmunization [4].

Treatment of ANCA-associated glomerulonephritis (ANCA GN) varies depending on the severity of the disease. The mainstay of treatment is immunosuppression. Standard therapy includes glucocorticosteroids in combination with cyclophosphamide and/or rituximab. Plasmapheresis is also popular for removing autoantibodies. After achieving remission, maintenance therapy is necessary. Patients are most commonly advised to continue with reduced doses of glucocorticosteroids combined with azathioprine or rituximab [3]. The optimal duration of maintenance therapy has not yet been established. According to the latest Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, therapy should last from 18 months to 4 years. Premature discontinuation of therapy increases the risk of disease relapse, while prolonged immunosuppression is associated with intensified side-effects [31].

**Glomerulonephritis Associated with Anti-Neutrophil Cytoplasmic Antibodies (ANCA) (ANCA-GN) post-COVID-19 recovery.** Initially, COVID-19 was recognized as an acute disease primarily affecting the lungs. It is now understood that the disease is more multifaceted, characterized by a wide range of symptom severity and affects people of all ages. Moreover, several organs are involved, but the kidneys are a particularly significant site of damage [12].

The exact pathogenesis of the development of this disease has not been fully elucidated. In patients with ANCA-positive vasculitis, a high level of circulating NETs has been documented in biopsy results. It is likely that extracellular neutrophil traps directly contribute to the development of vasculitis, damaging endothelial cells and activating the complement system, and indirectly through the production of PR3-ANCA and MPO-ANCA. This mechanism underscores the ability of SARS-CoV-2 to induce the autoimmunization phenomena, which can cause the occurrence or exacerbation of autoimmune renal vasculitis [11, 32, 33]. It is possible that COVID-19 masks the underlying genetic etiology and triggers an autoimmune process in genetically-susceptible patients [34, 35]. There are also mechanisms related to epitope spreading, leading to the induction of an immune response and consequently the production of ANCA antibodies and vasculitis [36, 37]. Furthermore, Cheng et al. confirmed this thesis in a prospective cohort study in which they observed that over 40% of hospitalized patients with Covid-19 had symptoms of kidney damage [10].

Since the COVID-19 pandemic, several cases of ANCA-positive vasculitis with renal involvement have been noted in the adult population without previous immunological disorders and following recent COVID-19 infections [38].

Banjongjit and others from the Nephrology Department at Vichaiyut Hospital in Bangkok, Thailand, published a

systematic review describing 23 cases of patients diagnosed with ANCA-associated glomerulonephritis (ANCA-GN) during hospitalization for SARS-CoV-2 infection, or a few months after COVID-19 infection worldwide. These patients were not previously vaccinated against COVID-19, ruling-out the possibility of vaccine-induced ANCA-GN. All patients presented with microscopic haematuria and proteinuria. Ten patients tested positive for myeloperoxidase (MPO)-ANCA, and seven showed positive results for proteinase-3 (PR3)-ANCA. One patient had mixed ANCA results. Five out of fourteen (36%) patients also had a positive antinuclear antibody (ANA) test; 14% of the patients had positive anti-glomerular basement membrane (anti-GBM) and p-ANCA antibodies, and 100% had a positive rheumatoid factor (RF) result. These patients showed varying degrees of elevated creatinine levels. Most of the patients demonstrated renal function improvement after immunosuppressive treatment. The authors concluded that there might be a link between SARS-CoV-2 infection and AAV and ANCA-GN, but they lacked sufficient research to make a definitive conclusion [13].

An important study by Chan L. from the Nephrology Department of the Icahn School of Medicine at Mount Sinai in New York, showed that 46% of 3,993 COVID-19 patients hospitalized in the USA developed acute kidney injury (AKI), and 19% required renal replacement therapy [39]. AKI is a common complication of COVID-19, with an incidence rate of up to 56.9% in cases involving renal involvement. The frequency of renal replacement therapy varies depending on the severity of AKI. However, there are few reported cases of COVID-19-associated vasculitis and even fewer of perinuclear anti-neutrophil cytoplasmic antibody (P-ANCA)-associated vasculitis [40, 41]. Given the prevalence of AKI in COVID-19, determining the primary etiology of renal damage can be challenging [41].

Research is ongoing to elucidate the impact of COVID-19 infection on autoimmune or vascular physiology. The disease likely possesses properties similar to those observed in autoimmune diseases, particularly in the production of extracellular neutrophil traps (NETs) containing pro-inflammatory proteins [42, 43]. Table 3 presents selected cases of ANCA-associated glomerulonephritis (ANCA-GN) following COVID-19 infection.

**Glomerulonephritis associated with ANCA following vaccination against SARS-CoV-2.** Vaccines against SARS-CoV-2 (COVID-19) have proven beneficial in mitigating COVID-19 disease and preventing the spread of the virus. Rare cases of ANCA-associated renal vasculitis induced by the COVID-19 vaccine have been described in the literature. Collective reports on the rarity of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) raise concerns about its association with COVID-19 vaccination. Several case reports have described ANCA-associated pauci-immune glomerulonephritis (ANCA-GN) following COVID-19 vaccination [48, 49].

The molecular mechanisms of vaccine-induced ANCA-associated renal vasculitis are not well-defined. The pathophysiology of this process involves several factors. It is assumed that adjuvant molecules in the vaccine may trigger an autoimmune response [50]. Activation of the complement system, molecular mimicry, systemic inflammatory response, defective neutrophil apoptosis, and polyclonal activation of immune cells triggered by the formation of extracellular

**Table 3.** Characteristics of selected cases of ANCA-associated glomerulonephritis (ANCA-GN) following COVID-19 infection

Authors	Date of publication	Case Details
Nupur N. Uppal et al. [38].	2020	Two cases of pauci-immune glomerulonephritis (GN) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, showing clinical improvement after COVID-19 treatment and cautious use of immunosuppressive drugs.
T. Izci Duran et al. [11].	2021	Two instances of ANCA-associated vasculitis following COVID-19 infection, with acute kidney injury and renal biopsies revealing necrotizing glomerulonephritis.
M. Jalalzadeh et al. [44].	2021	A 46-year-old woman with systemic sclerosis experienced renal failure following a COVID-19 diagnosis. Renal biopsy showed glomerulonephritis.
Eduardo Briones et al. [45].	2022	Anti-GBM antibodies in a patient with glomerulonephritis and COVID-19 suggest a temporal association with pulmonary injury.
Jeong-Yeun Lee, H. Hwang [46].	2023	A case of ANCA-associated glomerulonephritis in a patient with COVID-19.
A. Pokharel et al. [47].	2023	COVID-19 may be associated with pauci-immune glomerulonephritis. ANCA tests can be falsely negative..
Tahir A. et al. [41].	2023	ANCA-associated vasculitis in an older male with no known history of autoimmune diseases, following recent COVID-19 illness. Tests revealed elevated myeloperoxidase antibodies (MPO-AB) and perinuclear ANCA (p-ANCA), with biopsy confirming focal crescentic glomerulonephritis.

neutrophil traps and pro-inflammatory proteins may induce vasculitis in genetically susceptible individuals [32]. Reports suggest that COVID-19 vaccines, particularly mRNA vaccines, may potentially induce this disease. The vaccine may activate a cascade of pathways through dendritic and bone marrow cell stimulation, leading to autoinflammation [36, 50, 51]. Moreover, a series of cases showed that some patients developed dual-positive anti-GBM and MPO ANCA glomerulonephritis after mRNA COVID-19 vaccination, with outcomes varying from complete remission to dialysis dependence or death [5, 52].

A study by Laskova and colleagues suggests a potential link between COVID-19 vaccines and ANCA-associated glomerulonephritis, especially anti-MPO type, although further research is needed to confirm this [53]. There is also evidence suggesting that ANCA-associated vasculitis with pauci-immune crescentic glomerulonephritis may occur as a rare adverse effect following COVID-19 vaccination. In some cases, the condition was diagnosed after the second vaccine dose, and most cases achieved remission [48, 54].

Haoyue Cheng and others from the Department of Public Health and Department of Anaesthesiology at the Second Affiliated Hospital of Zhejiang University Medical School in China, in their latest meta-analysis of controlled clinical trials, confirmed the effectiveness of the COVID-19 vaccine in preventing disease and reducing severity. The safety profiles of COVID-19 vaccines were deemed acceptable. Furthermore, mRNA vaccines were considered the most effective, and the risk and severity of adverse events were minimal compared to severe symptoms caused by COVID-19. However, several cases of recurrent ANCA glomerulonephritis were recorded after COVID-19 vaccination [15].

An analysis of 29 cases by researchers from the Nephrology Department at Naresuan University in Thailand, led by Thammathiwat T., showed that ANCA-GN secondary to COVID-19 vaccination appeared more frequently in older women vaccinated with mRNA vaccines. The most common reported symptoms were abnormal urine sediment, fever, and general weakness. In over half of the studied cases, the following autoantibodies were confirmed: Coombs antibodies, ANA, and cryoglobulins. All patients responded well to treatment, with no fatalities. Most cases of ANCA GN after COVID-19 vaccination occurred after the second dose of the vaccine [48].

Billions of doses of COVID-19 vaccines have been administered worldwide, and ANCA-associated glomerulonephritis following this medical procedure is very rare. The benefits of COVID-19 vaccination outweigh the risk of potential autoimmune diseases. Thammathiwat and colleagues in their study emphasized the need to avoid unnecessary booster doses of COVID-19 vaccines in high-risk patients (carriers of HLA-DR4 or DRB4 alleles) [48, 55]. Renal vasculitis induced by the COVID-19 vaccine is rare, and mass vaccination against COVID-19 infection globally is the appropriate strategy to combat this serious viral disease [5]. Table 4 summarizes the published cases of ANCA-associated renal vasculitis after COVID-19 vaccination [55].

## CONCLUSIONS

In summary, ANCA-associated glomerulonephritis can be linked to both infection and vaccination, and the underlying mechanism may involve autoimmune reactions. Scientific research indicates that COVID-19 can be a triggering factor for autoimmune reactions, including ANCA-associated glomerulonephritis, although these mechanisms require further investigation. This mechanism may cause the occurrence or exacerbation of autoimmune renal vasculitis. It is possible that COVID-19 masks the underlying genetic etiology and initiates an autoimmune process in genetically susceptible individuals in whom there is a complex interplay of various environmental and epigenetic factors. Genetic associations of vasculitis with HLA-DP and HLA-DQ systems have been found, depending on the type of ANCA antibodies, namely PR3-ANCA and MPO-ANCA, respectively. The occurrence of this condition as a side-effect of COVID-19 vaccines seems rare, and the benefits of vaccination generally outweigh the risk of such adverse effects. Billions of people have been vaccinated worldwide, and ANCA-associated glomerulonephritis following COVID-19 vaccination has occurred infrequently. Vaccination becomes a triggering factor for an autoimmune process mainly in genetically predisposed individuals, similar to infections. This suggests that the benefits of COVID-19 vaccination outweigh the risk of potential autoimmune diseases and ANCA-GN. Further research and years of observation are needed to draw significant conclusions.

There is a lack of data allowing direct comparison of the incidence of ANCA glomerulonephritis after COVID-19 and after COVID-19 vaccination. Available studies and case reports mainly focus on individual cases or small case series, not on statistical comparisons of incidence rates. Table 5 compares the current state of knowledge on ANCA glomerulonephritis after COVID-19 and after COVID-19

**Table 4.** Reported cases of renal AAV induced by vaccination against SARS-CoV2 [55]

Team Leader	Year	Case Description
Anderegg M.A. et al. [51].	2021	PR3-ANCA pauci-immune crescentic GN in an 81-year-old male after the second dose of mRNA-1273 vaccine.
Dube G.K. et al. [56].	2021	MPO-ANCA pauci-immune crescentic GN in a 29-year-old female, 16 days post-second dose of BNT162b2 mRNA vaccine.
Feghali E.J. et al. [57].	2021	ANCA GN associated with anti-PR3 in a 58-year-old male, 4 days after the second dose of mRNA-1273 vaccine.
Hakroush S. et al. [54].	2021	MPO-ANCA-associated vasculitis, pauci-immune crescentic GN in a 79-year-old female, 2 weeks post-second dose of BNT162b2 mRNA vaccine.
Ritter A. et al. [58].	2021	MPO-ANCA AAV with massive rhabdomyolysis and GN in a 69-year-old male, 33 days after the second dose of BNT162b2 mRNA vaccine.
Sekar A. et al. [50].	2021	PR3-ANCA pauci-immune necrotizing GN with crescents in a 52-year-old male, 2 weeks after the second dose of mRNA-1273 vaccine.
Shakoort MT. et al. [49].	2021	Renal-limited MPO-AAV in a 78-year-old female, 2 weeks after the second dose of BNT162b2 mRNA vaccine.
Willa M. et al. [59].	2021	Pauci-immune GN associated with P-ANCA in a 63-year-old male, 1 week after the first dose of ChAdOx1 nCoV-19 vaccine.
Al-Yafeai Z. et al. [60].	2022	PR3-ANCA-associated vasculitis in a 62-year-old female, 4 weeks after the first dose of BNT162b2 mRNA vaccine.
Cano-Gómez T. et al. [61].	2022	Rapidly progressive GN associated with MPO-ANCA in a 51-year-old female, after the third dose of ChAdOx1 nCoV-19 vaccine.
Christodoulou M. et al. [62].	2022	MPO-ANCA lung-renal syndrome and rapidly progressive GN in a 72-year-old female, 2 weeks after the second dose of mRNA-1273 vaccine.
Prabhakar A. et al. [36].	2022	PR-3 AAV GN with crescents in a 51-year-old male, 15 days after the first dose of ChAdOx1 nCoV-19 vaccine.
So D. et al. [63].	2022	MPA with elevated anti-MPO antibodies and GN in a 42-year-old male after the second dose of BNT162b2 vaccine.
Suzuki M. et al. [64].	2022	MPO-AAV with severe, pauci-immune crescentic GN in a 72-year-old male, 1 day after the second dose of BNT162b2 mRNA vaccine.
Kawamura T. et al. [65].	2023	MPO-ANCA, rapidly progressive GN in a 71-year-old female, 1 week after the second dose of BNT162b2 mRNA vaccine.

vaccination. Due to limited data, this table does not include specific numerical data because most available studies do not provide sufficient data to make a statistically reliable comparison. Additional detailed epidemiological studies are required to obtain accurate and comparable data.

**Table 5.** Summary of the current state of knowledge on ANCA glomerulonephritis after COVID-19 and after COVID-19 vaccination

Criterion	ANCA Glomerulonephritis Post COVID-19	ANCA Glomerulonephritis Post COVID-19 Vaccination
No. of published cases	Information on the number of cases is limited and often comes from individual reports or small case series.	Similarly, the information mainly comes from reports of individual cases, or small case series.
Incidence rate	There is insufficient data to determine the overall incidence rate	There is also insufficient data to determine the overall incidence rate.
Direct comparison of incidence	Direct comparison is not available in the scientific literature.	Direct comparison is not available in the scientific literature.

Source: prepared based on this article

Establishing a causal link between SARS-CoV-2 infection and renal involvement in ANCA-associated vasculitis also requires further research.

## REFERENCES

- Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. *CJASN*. 2017;12(10):1680–91. <https://doi.org/10.2215/CJN.02500317>
- He X, Wen Y, Hu R, Wu H, Ye W, Yue C, et al. Interstitial nephritis without glomerulonephritis in ANCA-associated vasculitis: a case series and literature review. *Clin Rheumatol*. 2022;41(11):3551–63. <https://doi.org/10.1007/S10067-022-06264-2>
- Molnár A, Studinger P, Ledó N. Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies. *Front Med*. 2022;9:884188. <https://doi.org/10.3389/FMED.2022.884188>
- Scott J, Hartnett J, Mockler D, Little MA. Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review. *Autoimmun Rev*. 2020;19(11):102660. <https://doi.org/10.1016/J.AUTREV.2020.102660>
- Uddin K, Mohamed KH, Agboola AA, Naqvi WA, Hussaini H, Mohamed AS, et al. Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Renal Vasculitis Following COVID-19 Vaccination: A Case Report and Literature Review. *Cureus* 2022;14(10): e30206. <https://doi.org/10.7759/CUREUS.30206>
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *NEJM* 2020;382(13):1199–1207. <https://doi.org/10.1056/NEJMOA2001316>
- Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. *J Autoimmun*. 2020;109:102434. <https://doi.org/10.1016/J.JAUT.2020.102434>
- COVID-19 cases | WHO COVID-19 dashboard n.d. <https://data.who.int/dashboards/covid19/cases?n=c> (accessed 2024.01.20.).
- Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyan S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. *Rev Med Virol*. 2021;31(3):e2176. <https://doi.org/10.1002/RMV.2176>
- Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020;97(5):829–838. <https://doi.org/10.1016/j.kint.2020.03.005>
- Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. *Rheumatol Int*. 2021;41(8):1523–1529. <https://doi.org/10.1007/S00296-021-04914-3>
- Gambella A, Barreca A, Biancone L, Roccatello D, Peruzzi L, Besso L, et al. Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. *Biomolecules*. 2022;12(2):298. <https://doi.org/10.3390/BIOM12020298>
- Banjongit A, Thammathiwat T, Townamchai N, Kanjanabuch T. SARS-CoV-2 infection associated with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN): a systematic review and two case reports. *J Nephrol*. Published online 6 November 2023;1–11. <https://doi.org/10.1007/S40620-023-01777-8>
- Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. *NEJM*. 2020;382(21):1969–1973. <https://doi.org/10.1056/NEJMP2005630>
- Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and safety of covid-19 vaccines in phase iii trials: A meta-analysis. *Vaccines* 2021;9(6):582. <https://doi.org/10.3390/VACCINES9060582>
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *NEJM*. 2020;383(27):2603–2615. <https://doi.org/10.1056/NEJMOA2034577>
- Turkmen K, Ozer H, Tesar V. An update on diagnosis and treatment of ANCA associated renal vasculitis. *Int Urol Nephrol*. 2023;55(11):2817–2827. <https://doi.org/10.1007/S11255-023-03565-6>
- Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. *Am J Kidney Dis*. 2020;75(1):124–137. <https://doi.org/10.1053/J.AJKD.2019.04.031>
- Aydin Z, Turkmen K, Dede F, Yasar E, Ozturk S, Aydin M, et al. Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group. *Clin Exp Nephrol*. 2021;25(2):173–183. <https://doi.org/10.1007/S10157-020-01978-6>
- Tanna A, Pusey CD. The Histopathological Classification of ANCA-associated Glomerulonephritis Comes of Age. *J Rheumatol*. 2017;44(3):265–267. <https://doi.org/10.3899/JRHEUM.170006>
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013;65(1):1–11. <https://doi.org/10.1002/ART.37715>
- Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. *Nat Rev Dis Primers*. 2020;6(1):1–27. <https://doi.org/10.1038/s41572-020-0204-y>
- Wallace ZS, Stone JH. Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide? *Front Immunol*. 2019;10:2855. <https://doi.org/10.3389/FIMMU.2019.02855>
- Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, Astle W, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. *Nat Commun*. 2019;10(1):1–13. <https://doi.org/10.1038/s41467-019-12515-9>
- Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis. *Front Immunol*. 2021;12:624848. <https://doi.org/10.3389/FIMMU.2021.624848>
- Jeffs LS, Nitschke J, Tervaert JWC, Peh CA, Hurtado PR. Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation. *Clin Rheumatol*. 2016;35(4):943–951. <https://doi.org/10.1007/S10067-015-3073-0>
- Huugen D, Xiao H, Van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, et al. Aggravation of Anti-Myeloperoxidase Antibody-Induced Glomerulonephritis by Bacterial Lipopolysaccharide: Role of Tumor Necrosis Factor- $\alpha$ . *Am J Pathol*. 2005;167(1):47–58. [https://doi.org/10.1016/S0002-9440\(10\)62952-5](https://doi.org/10.1016/S0002-9440(10)62952-5)
- Lee SW, Kim DY, Ahn SH, Park YB, Han KH, Park JY. HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. *Rheumatol Int*. 2018;38(8):1531–1538. <https://doi.org/10.1007/S00296-018-4043-Z>
- Fujita M, Hatachi S, Yagita M. Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. *Lupus*. 2009;18(2):164–168. <https://doi.org/10.1177/09612033080906069>
- Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CGM. Association of chronic nasal carriage of *Staphylococcus aureus* and higher relapse rates in Wegener granulomatosis. *Ann Intern Med*. 1994;120(1):12–17. <https://doi.org/10.7326/0003-4819-120-1-199401010-00003>
- Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4):S1–276. <https://doi.org/10.1016/J.KINT.2021.05.021>
- Söderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. *Front Immunol*. 2016;7(JUN):256. <https://doi.org/10.3389/FIMMU.2016.00256>
- Rath P, Shriber S, Hastings A, C Marshall T, Lane J, P Wiles S, et al. A rare case of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis in the setting of COVID-19 infection. *Chest*. 2022;162(4):A65–A66. <https://doi.org/10.1016/J.CHEST.2022.08.038>
- Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. *Curr Opin Rheumatol*. 2021;33(2):155–162. <https://doi.org/10.1097/BOR.0000000000000776>
- Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020;5(11):e138999. <https://doi.org/10.1172/JCI.INSIGHT.138999>
- Prabhakar A, Naidu GRSR, Chauhan P, Sekar A, Sharma A, Sharma A, et al. ANCA-associated vasculitis following ChAdOx1nCoV19 vaccination: case-based review. *Rheumatol Int*. 2022;42(4):749–758. <https://doi.org/10.1007/S00296-021-05069-X>
- Yadav R, Shah S, Chhetri S. ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine. *Ann Med Surg*. 2022;79:104123. <https://doi.org/10.1016/J.AMSU.2022.104123>
- Uppal NN, Kello N, Shah HH, Khanin Y, De Oleo IR, Epstein E, et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. *Kidney Int Rep*. 2020;5(11):2079–2083. <https://doi.org/10.1016/J.EKIR.2020.08.012>
- Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19. *J Am Soc Nephrol*. 2021;32(1):151–160. <https://doi.org/10.1681/ASN.2020050615>
- Głowacka M, Lipka S, Młynarska E, Franczyk B, Rysz J. Acute Kidney Injury in COVID-19. *Int J Mol Sci*. 2021;22(15):8081. <https://doi.org/10.3390/IJMS22158081>

41. Tahir A, Walia J, Daly T, Gradzka A, Banai R, Tahir A, et al. Rapidly Progressive Glomerulonephritis: A COVID-19 Case Report. *Cureus*. 2023;15(4):e37767. <https://doi.org/10.7759/CUREUS.37767>
42. Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J, et al. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. *Angiogenesis*. 2021;24(4):755–788. <https://doi.org/10.1007/S10456-021-09805-6>
43. Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-Associated Vasculitis: An Update. *J Clin Med*. 2021;10(7):1446. <https://doi.org/10.3390/JCM10071446>
44. Jalalzadeh M, Valencia-Manrique JC, Boma N, Chaudhari A, Chaudhari S, Jalalzadeh M, et al. Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a Case of Scleroderma After Recent Diagnosis With COVID-19. *Cureus*. 2021;13(1):e12485. <https://doi.org/10.7759/CUREUS.12485>
45. Briones E, Méndez GP, Laguna J, Vargas M, Briones E, Méndez GP, et al. Association of COVID-19 and glomerulonephritis with ANCA and anti-glomerular basement membrane antibodies: Report of one case. *Rev Med Chil*. 2022;150(6):828–831. <https://doi.org/10.4067/S0034-98872022000600828>
46. Lee JY, Hwang HS. Acquired antineutrophil cytoplasmic antibody-associated glomerulonephritis after COVID-19 infection. *Kidney Res Clin Pract*. 2023;42(3):405–408. <https://doi.org/10.23876/j.krcp.22.261>
47. Pokharel A, Metcalf BD, Li W, Kanaan HD, Zhang PL. COVID-19 Infection Can be Associated with Pauci-Immune Type of Crescentic Glomerulonephritis: A Case Report. *AJCP*. 2023;160(Supplement\_1):S105–S106. <https://doi.org/10.1093/AJCP/AQAD150.232>
48. Thammathiwat T, Banjongjit A, Iampenkhae K, Townamchai N, Kanjanabuch T. ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review. *Vaccines*. 2023;11(5):983. <https://doi.org/10.3390/VACCINES11050983>
49. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. *Am J Kidney Dis*. 2021;78(4):611–613. <https://doi.org/10.1053/J.AJKD.2021.06.016>
50. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. *Kidney Int*. 2021;100(2):473–474. <https://doi.org/10.1016/J.KINT.2021.05.017>
51. Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. *Kidney Int*. 2021;100(2):474–476. <https://doi.org/10.1016/J.KINT.2021.05.016>
52. Ting JA, Barbir EB, McRae SA, Schachter M, De Luca L, Riazzy M, et al. Double-Positive Anti-Glomerular Basement Membrane Antibody and Myeloperoxidase Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Post COVID-19 mRNA vaccine: A Case Series of 4 Patients. *Can J Kidney Health Dis*. 2023;10:20543581231153217. <https://doi.org/10.1177/20543581231153217>
53. Laskova A, Mohammed B, Ali F, Syritsa B. AB0629 Glomerulonephritis associated with ANCA after COVID-19 vaccine: a systematic review. *Ann Rheu Dis*. 2022;81(Suppl\_1):1441–1432. <https://doi.org/10.1136/ANNRHEUMDIS-2022-EULAR.3379>
54. Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. *Front Immunol*. 2021;12:762006. <https://doi.org/10.3389/FIMMU.2021.762006>
55. Moronti V, Carubbi F, Sollima L, Piscitani L, Ferri C. End stage renal disease in patient with microscopic polyangiitis and atypical hemolytic-uremic syndrome arose 3 weeks after the third dose of anti-SARS-CoV2 vaccine mRNA-1273: A case report with literature revision. *Medicine*. 2023;102(50):e36560. <https://doi.org/10.1097/MD.0000000000036560>
56. Dube GK, Benvenuto LJ, Batal I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine. *Kidney Int Rep*. 2021;6(12):3087–3089. <https://doi.org/10.1016/J.EKIR.2021.08.012>
57. Feghali EJ, Zafar M, Abid S, Santoriello D, Mehta S. De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19. *Cureus*. 2021;13(11):e19616. <https://doi.org/10.7759/CUREUS.19616>
58. Ritter A, Helmchen B, Gaspert A, Bleisch J, Fritsch B, Buchkremer F, et al. Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines. *Clin Kidney J*. 2022;15(5):961–973. <https://doi.org/10.1093/CKJ/SFAB284>
59. Villa M, Díaz-Crespo F, Pérez de José A, Verdalles Ú, Verde E, Almeida Ruiz F, et al. A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality? *Kidney Int*. 2021;100(4):937–938. <https://doi.org/10.1016/J.KINT.2021.07.026>
60. Al-Yafeai Z, Horn BJM, Terracaine W, Jose A, Krishnan P. A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination. *Cureus*. 2022;14(3):e23162. <https://doi.org/10.7759/CUREUS.23162>
61. Cano-Gámez T, Teco-Cortes JA, Soto-Abraham MV, Álvarez-Hernández E. SARS-CoV-2 Vaccination as a Trigger for Perinuclear Antineutrophil Cytoplasmic Antibodies (p-ANCA) Associated With Rapidly Progressive Glomerulonephritis. *Cureus*. 2022;14(10):e29924. <https://doi.org/10.7759/CUREUS.29924>
62. Christodoulou M, Iatridi F, Chalkidis G, Lioulis G, Nikolaidou C, Badis K, et al. ANCA-Associated Vasculitis May Result as a Complication to Both SARS-CoV-2 Infection and Vaccination. *Life*. 2022;12(7):1072. <https://doi.org/10.3390/LIFE12071072>
63. So D, Min KW, Jung WY, Han SW, Yu MY. Microscopic Polyangiitis Following mRNA COVID-19 Vaccination: A Case Report. *J Korean Med Sci*. 2022;37(19):e154. <https://doi.org/10.3346/JKMS.2022.37.E154>
64. Suzuki M, Sekiguchi Y, Sasaki M, Inaba S, Oyama S, Inoue Y, et al. Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech. *Inter Med*. 2022;61(19):2925–2929. <https://doi.org/10.2169/INTERNALMEDICINE.9807-22>
65. Kawamura T, Nakazawa D, Nishio S, Isozaki T, Komatsumoto M, Atsumi T. Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1\*09:01 allele. *Mod Rheumatol Case Rep*. 2023;7(2):426–430. <https://doi.org/10.1093/MRCR/RXAC093>